The immunopathogenesis of multiple sclerosis and Guillain-Barre syndrome

Current Opinion in Neurology

Volumn 9, Issue 3, 1996, Pages 165-177

  Giovannoni, Gavin ^a   Hartung, Hans Peter ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEAT SHOCK PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; DEMYELINATING DISEASE; DISEASE COURSE; ENDOTHELIUM CELL; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; REVIEW; T LYMPHOCYTE;

EID: 0029947672     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199606000-00004     Document Type: Review

References (134)

1. Compston DAS, Kellar Wood H, Robertson M, Sawcer S, Wood NW: • Genes and susceptibility to multiple sclerosis. Acta Neurol Scand 1995, 161(suppl):43-51. Comprehensive and current literature review on genes and susceptibility to MS.
2. Challoner PB, Smith KT, Parker JD, Macleod DL, Coulter SN, Rose TM, • Schultz ER, Bennett JL, Garber RL, Chang M et al.: Plaque-associated expression of human herpesvlrus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995, 92:7440-7444. Exciting discovery of a possible aetiological role of HHV-6 in MS.
3. Theofilopoulos AN: The basis of autoimmunity. Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995, 16:90-98.
4. Wucherpfennig KW, Strominger JL: Molecular mimicry in T cell-mediated •• autoimmunity: viral peptides activate human T cell clones specific for myeline basic protein. Cell 1995, 80:695-705. These authors identified peptide motifs required for MHC class II binding and TCR recognition of the immunodominant MBP(85-99) peptide. These were comparable with a protein database for viral and bacterial pathogens that could be relevant to inflammatory disease of the central nervous system. MBP(85-99). specific T-cell clones could be activated by mimicry peptides of herpes simplex, Epstein-Barr virus, adenovirus 12, influenza type A and Pseudomonas aeruginosa. Viral mimicry peptides were more effectively presented by MS-associated DR2 molecules. Activation of MBP-specific T-cells by viral peptides would constitue a mechanism by which autoimmune responses are triggered in MS.
5. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, •• Weiner HL, Nabavi N, Glimcher LH: B7-1 and B7-2 co-stimulatory molecules activate differentially the Th-1/Th-2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718. Very important findings documenting the different T-helper developmental pathways and the potential therapeutic implications from manipulating their development.
6. Cross AH, Girard TJ, Giacoletto KS, Evans RJ, Keeling RM, Lin RF, Trotter JL, Karr RW: Long-term Inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 co-stimulation. J Clin Invest 1995, 95:2783-2789.
7. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ: Distinct roles for B7-1 (CD80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitls. J Clin Invest 1995, 96:2195-2203.
8. De Simone R, Giampaolo A, Gallo P, Levi G, Peschle C, Aloisi F: The co-stimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J Neuropathol Exp Neurol 1995, 50:175-187.
9. Hohlfeld R, Meinl E, Weber F, Zipp F, Schmidt S, Sotigiu S, Goebels N, Voltz R, Spuler S, Iglesias A, Wekerle H: The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology 1995, 45(suppl 6):S33-S38.
10. Martin R, McFarland HF: Immunological aspects of experimental allergic •• encephalomyelitls and multiple sclerosis. Crit Rev Clin Lab Sci 1995, 32:121-182. An excellent authoritative review with 384 references.
11. Lodge PA, Allegretta M, Steinman L, Subramaniam S: Myelin basic protein specficlty and T-cell receptor gene usage of HPRT mutant T-cell clones in patients with multiple sclerosis. Ann Neurol 1994, 36:734-740.
12. van den Berg LH, Mollee I, Wokke JH, Logtenberg T: Increased frequencles of HPRT mutant T lymphocytes in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 1995, 58:37-42.
13. Oksenberg JR, Panzara MA, Begovich AB, Mitchell D, Erlich HA, Murray RS, Shimonkevitz R, Sherritt M, Rothbard J, Bernard CCA, Steinman L: Selection for T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 1993, 362:68-70
14. Kalman B, Alder H, Lublin FD: Characteristics of the T lymphocytes involved in experimental allergic encephalomyelitls. J Neuroimmunol 1995, 61:107-116.
15. Kondo T, Yamamura T, Inobe J, Ohashi T, Takahashi K, Tabira T: TCR repertoire to proteolipid protein (PLP) in multiple sclerosis (MS): homologies between PLP-specific T cells and MS-associated T cells in TCR junctional sequences. Int Immunol 1996, 8:123-130.
16. Wucherpfennig KW, Hafler DA: A review of T-cell receptors in multiple sclerosis: clonal expansion an persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann NY Acad Sci 1995, 756:241-258.
17. Allegretta M, Steinman L: Unique T-cell receptor junctional sequences found in multiple sclerosis and T-cells mediating experimental allergic encephalomyelitls. Ann NY Acad Sci 1995, 756:265-282.
18. Utz U, Martin R, Brooks JA, Biddison WE, McFarland HF: T-cell receptor use in multiple sclerosis. Ann NY Acad Sci 1995, 756:259-264.
19. Linington C, Waksman B: The T-cell receptor in multiple sclerosis. Ann N Y Acad Sci 1995, 756:294-306.
20. Gold R, Giegerich G, Hatrung H-P, Toyka KV: T-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR β-chain-variable-region Vβ8.2-positive T cells are not essential for induction and course of disease. Proc Natl Acad Sci U S A 1995, 92: 5850-5854.
21. Brod SA, Khan M, Bright J, Sriram S, Marshall GD, Henninger EM, Kerman RH, Wolinsky JS: Decreased CD3-mediated interferon-γ production in relapsing-remitting multiple sclerosis. Ann Neurol 1995, 37:546-549.
22. Olsson T: Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995, 45(suppl 6):S11-S15.
23. + memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol 1995, 2: 249-252.
24. + cells mediate active suppression. J Immunol 1995, 155:910-916.
25. + T-cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci U S A 1994, 91:10859-10863.
26. Koh DR, Fung Leung WP, Ho A, Gray D, Acha Orbea H, Mak TW: Less mortality but more relapses in experimental allergic encephalomyelitis. Science 1992, 256:1210-1213.
27. + T-cells in murine experimental allergic encephalomyelitis. Science 1992, 256:1213-1215.
28. + T cells is mediated by interferon-γ and is defective in chronic progressive multiple sclerosis. J Clin Invest 1995, 95:2211-2719.
29. Li F, Linan MJ, Stein MC, Faustman DL: Reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes. Ann Neurol 1995, 38:147-154.
30. Martin R, McFarland HF: Multiple sclerosis: are HLA class I molecules involved in disease pathogenesis? Ann Neurol 1995, 38:137-139.
31. Bauer J Wekerle H, Lassmann H: Apoptosis in brain-specific autoimmune disease. Curr Opin Immunol 1995, 7:839-843.
32. Zettl UK, Gold R, Hartung HP, Toyka KV: Apoptotic cell death of T lymphocytes in experimental autoimmune neuritis. Neurosci Lett 1994, 176:75-79.
33. Zettl UK, Gold R, Hartung HP, Toyka KV: Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis. J Neuropathol Exp Neurol 1995, 54:540-547.
34. Zettl UK, Gold R, Toyka KV, Hartung HP: in situ demonstration of T-cell activation and elimination in the peripheral nervous system during experimental autoimmune neuritis in the Lewis rat Acta Neuropathol (Berlin) 1996, 91:360-367.
35. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA: γδT-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci U S A 1992, 89:4588-4592.
36. Stinissen P, Vandevyver C, Medaer R, Vandegaer L, Nies J, Tuyls L, Hafler DA, Raus J, Zhang J: Increased frequency of γδT cells in cerebrospinal fluld and peripheral blood of patients with multiple sclerosis. J Immunol 1995, 154:4883-4894.
37. Battistini L, Selmaj J, Kowal C, Ohmen J, Modlin RL, Raine CS, Brosnan CF: Multiple sclerosis: limited diversity of the Vδ2-Jδ3 T-cell receptor in chronic active lesions. Ann Neurol 1995, 37:198-203.
38. Munschaur FE, Hartrich LA, Stewart CC, Jacobs L: Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol 1995, 62:177-181.
39. Rees JH, Gregson NA, Hughes RAC: Anti-ganglioside GM1 antibodies in • Quillain-Barré syndrome and their relationship to Campylobecter jejuni infection. Ann Neurol 1995, 38:809-816. Confirmation of the link between anti-GM1 antibodies and C. jejuni infection in patients with GBS.
40. + currents in isolated rat myelinated nerve fibers. Ann Neurol 1995, 37:436-442. A demonstration of the functional effects of anti-GM1 antibodies on ion-channel function.
41. Wirguin I, Rosoklija G, Trojaborg W, Hays AP, Latov N: Axonal degeneration accompanied by conduction block induced toxin mediated Immune reactivity to GM1 ganglioside in rat nerves. J Neurol Sci 1995, 130:17-21.
42. Harvey GK, Toyka KV, Zielasek J, Kiefer R, Simonis C, Hartung-HP: Failure of anti-GM1 lgG or lgM to induce conduction block following intraneural transfer. Muscle Nerve 1995, 18:388-394.
43. •].
44. •] demonstrate the probable functional effects of anti-GQ1b antibodies on neuromuscular transmission, widening the spectrum of autoimmune phenomena occurring at this site.
45. Spies JM, Pollard JD, Bonner JG, Westland KW, Mcleod JG: Synergy between antibody and P2-reactive T cells in experimental allergic neuritis. J Neuroimmunol 1995, 57:77-84.
46. Cuzner ML, Loughlin AJ, Mosely K, Woodroofe MN: The role of mlcroglla in the processes of inflammatory demyelination and remyelination. Neuropathol Appl Neurobiol 1994, 20:200-201.
47. Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H: Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995, 38:788-796.
48. Svenningsson A, Hansson GK, AndersenO, Andersson R, Patarroyo M, Stemme S: Adhesion molecule expression on cerebrospinal fluid T lymphocytes: evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls. Ann Neurol 1993, 34:155-61.
49. Oksaranta O, Tarvonen S, llonen J, Poikonen K, Reunanen M, Panelius M, Salonen R: Influx of nonactivated T lymphocytes into cerebrospinal fluid during relapse of multiple sclerosis. Ann Neurol 1995, 38:465-468.
50. Cross AH, O'Mara T, Raine CS: Chronological localisation of myelin-reactive cells in the lesions of relapsing EAE Neurology 1994, 43:1028-1033.
51. Bauer J, Huittinga I, Zhao W, Lassmann H, Hickey WF, Dijkstra CD: The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 1995, 15:437-446.
52. Hart MN, Fabry Z: CNS antigen presentation. Trends Neurosci 1995, 18:475-481.
53. Gold R, Toyka KV, Hartung H-P: Synergistic effect of IFNγ and TNFα expression of immune molecules and antigen presentation by Schwann cells. Cellular Immunol 1995, 156:65-70.
54. Hartung H-P, Kiefer R, Gold R, Toyka KV: Autoimmunity in the peripheral nervous system. Baillière's Clin Neurol 1996, 5:1-46.
55. Hartung H-P, Archetos JJ, Zielasek J, Gold R, Koltzenburg M, Reiners K-H, Toyka KV: Circulating adhesion molecules and inflammatory mediators in demyelination. Neurology 1995, 45(suppl 6):S22-S32.
56. Cannella B, Raine CS: The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neural 1995, 37:424-35.
57. Koch AE, Halioran MM, Haskell CJ, Shah MR, Pllverini PJ: Angiogenesls • mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995, 376:517-519. Important immunological finding of a functional role for soluble E-selection and VCAM-1.
58. Dore-Duffy P, Newman W, Balabanov R, Lisak RP, Mainolfi E, Rothlein R, Peterson M: Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neural 1995, 37:55-62.
59. Giovannoni G, Thorpe JW, Kidd D, Kendall BE, Mosely IF, Thompson AJ, Keir G, Miller DH, Feldmann M, Thompson EJ: Soluble E-selectin in multiple sclerosis: raised levels in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996, 60:20-26.
60. Hartung H-P, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, Pflughaupt KW, Toyka KV: Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995, 38:186-193.
61. Martin S, Rieckmann P, Melchers I, Wagner R, Bertrams J, Voskuyl AE, Roep BO, Zielasek J, Heidenthal E, Weichselbraum I, et al.: Circulating forms of ICAM-3 (clCAM3). Elevated levels in autoimmune diseases and lack of association with clCAM-1. J Immunol 1995, 154:1951-1955.
62. Matsuda M, Tsukada N, Miyagi K, Yanagisawa N: Increased levels of soluble vascular adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1 -associated myelopathy. J Neuroimmunol 1995, 59:35-40.
63. Hartung H-P, Reiners K, Michels M, Hughes RAC, Heidenreich F, Zielasek J, Enders U, Toyka KV: Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies. Neurology 1994, 44:1153-1158.
64. Oka N, Akiguchi I, Kawasaki T, Ohnishi K, Kimura J: Elevated serum levels of endothelial leukocyte adhesion molecules in Guillain-Barré syndrome and chronic Inflammatory demyelinating polyneuropathy. Ann Neurol 1994, 35:621-624.
65. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N: Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992, 356:63-66.
66. Archelos JJ, Jung S, Mäurer M, Schmied M, Lassmann H, Tamatani T, Miyasaka M, Toyka KV, Hartung H-P: Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular molecule ICAM-1. Ann Neurol 1993, 34:145-154.
67. Archelos JJ, Mäurer M, Jung S, Toyka KV, Hartung H-P: Suppression of experimental autoimmune neuritis by antibodies to intercellular adhesion molecule ICAM-1. Brain 1993, 116:1043-1058.
68. Gordon EJ, Myers KJ, Dougherty JP, rosen H, Ron Y: Both anti-CD11 a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 1995, 62:153-160.
69. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, Homer HC: A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995, 58: 1-10.
70. Godiska R, Chantry D, Gray PW: Chemokine expression in murine allergic encephalomyelitis. J Neuroimmunol 1995, 58:167-176.
71. Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K: Macrophage inflammatory protein-1α in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci 1995, 129:223-227.
72. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994, 76:241-251.
73. Redford EJ, Hall SM, Smith KJ: Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 1995, 118:869-878.
74. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Lüer W, Helwig A, Poser S: Tumor necrosis factor-α messenger RNA expression in patients with multiple sclerosis Is associated with disease activity. Ann Neurol 1995, 37:82-88.
75. Navikas V, He B, Link J, Haglund M, Söderström M, Fredrickson S, Ljungdahl Å, Höjeberg B, Qiao J, Olsson T, Link H: Augmented expression of tumour necrosis factor-α and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. Brain 1996, 119:213-223.
76. Panitch HS, Hirsch RL, Haley AS, Johnson KP: Exacerbations of multiple sclerosis in patients treated with gamma Interferon. Lancet 1987, 1:893-895.
77. 2+-dependent mechanism. J Neuroimmunol 1995, 62:169-176.
78. + T cells. Ann Neurol 1995, 38:723-730. Important report demonstrating that DR2-positive individuals are high producers of the proinflammatory and myelinotoxic cylokine TNFα and lymphotoxin (TNFβ). Interestingly, no difference was seen between MS patients and healthy control individuals. Furthermore, high production was noted in both MBP-reactive and tetanus toxoid-reactive T-cell clones and is therefore not related to (auto)antigen specificity. This would suggest that augmented synthesis of TNF is not a result of high-affinity interaction of immunodominant MBP epitopes and DR2 gene products.
79. Raine CS: Multiple sclerosis: TNF revisited, with promise. Nature Med • 1995, 1:211-214. A review of the role of TNF in EAE and MS, as well as an editorial accompanying a paper on the antidepressant rolipram which suppresses the production of TNF and prevents EAE.
80. Link J, Söderström M, Olsson T, Höjeberg B, Ljungdahl Å, Link H: Increased transforming growth factor-β, interleukin-4, and interferon-γ in multiple sclerosis. Ann Neurol 1994, 36:379-386.
81. Söderström M, Hillert J, Link J, Navikas V, Fredrikson S, Link H: Expression of IFN-γ and TGF-β in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. Multiple Sclerosis 1995, 1:173-180.
82. Kiefer R, Funa K, Schweitzer T, Jung S, Bourde O, Toyka KV, Hartung H-P: Transforming growth factor-β1 in experimental autoimmune neuritis. Am J Pathol 1996, 148:211-223.
83. Johns TG, de Rosbo NK, Menon KK, Abo S, Gonzalves MF, Bernard CCA: Myelin ollgodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol 1995, 154:5536-5541.
84. Hilton AA, Slavin AJ, Hilton DJ, Bernard CCA: Characterisation of cDNA and genomic clones encoding human myelin oligodendrocyte glycoprotein. J Neurochem 1995, 65:309-318.
85. Van Noort JM, van Sechel AC, Bajramovic JJ, Ouagmiri ME, Polman CH, • Lassmann H, Ravid R: The small heat-shock protein αB-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995, 798-801. Discovery of a potentially new non-myelin autoantigen in MS. αB-crystallin is a heat-shock protein and its expression is increased nonspecifically in numerous inflammatory and degenerative diseases of the central nervous system.
86. Steinman L: Presenting an odd autoantigen. Nature 1995, 739-740.
87. Warren KG, Catz I, Johnson E, Mielke B: Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple slcerosis. Ann Neurol 1994, 35:280-289.
88. Warren KG, Catz I: Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and sclerosis cerebrospinal fluid. J Neurol Sci 1994, 121:137-153.
89. Hartung H-P, Pollard JD, Harvey GK, Toyka KV: Immunopathogenesis and • treatment of the Guillain-Barré syndrome. Part I. Muscle Nerve 1995, 18:137-153. Comprehensive review of aberrant humoral and cellular immune responses in peripheral nerve. The authors discuss induction, amplification and effector mechanisms in the animal model EAN and the human disease.
90. Pette M, Gengaroli C, Hartung H-P, Greiner A, Giegerich G, Toyka KV: Human T lymphocytes distinguish bovine from human P2 peripheral myelin protein: implications for immunological studies on inflammatory demyelinating neuropathies. J Neuroimmunol 1994, 52:47-52.
91. Pette M, Linington C, Gengaroli C, Grosse-Wilde H, toyka KV, Hartung H-P: T lymphocyte recognition sites on peripheral nerve myelin PO protein. J Neuroimmunol 1994, 54:29-34.
92. Weishaupt A, Giegerich G, Jung S, Gold R, Enders U, Pette M, Hayasaka K, Hartung H-P, Toyka KV: T cell antigenic and neuritogenic activity of recombinant human peripheral myelin P2 protein. J Neuroimmunol 1995, 63:149-156.
93. ••]
94. ••]
95. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, •• Asbury AK, Griffin JW: Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996, 39:625-635. The Chinese-US American collaboration of neurologists from Shijiazhuang, Johns Hopkins and University of Pennsylvania continues to provide first-class studies on the pathology of GBS as encountered in northern China. In exquisitely well-preserved autopsy material, the authors applied classical, electron microscopical and immunological techniques to delineate salient differential features of nerve pathology that may account for the heterogeneity of GBS (acute inflammatory demyelinating versus axonal versus acute motor axonal). Refer to text and Fig. 3.
96. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G: Determinant spreading and the dynamics of autoimmune T-cell repertoire. Immunol Today 1993, 14:203-207.
97. Panitch H: Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994, 36:S25-S8.
98. Runmarker B, Andersen O: Pregnancy Is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995, 118:253-261.
99. Hartung H-P, Pollard JD, Harvey GK, Toyka KV: Immunopathogenesis and • treatment of the Guillain-Barré syndrome-Part II. Muscle Nerve 1995, 18:154-164. Second part of a comprehensive review focusing on the link between C. jejuni infection and GBS. Broad coverage of treatment trials in GBS and overview of general management.
100. Rees J, Soudain SE, Gregson NA, Hughes RAC: Campylobacter jejuni •• infection and Guillain-Barré syndrome. N Engl J Med 1995, 333: 1374-1379. Definitive study. A prospective series of over 100 GBS patients, demonstrating a more severe course with a worse prognosis in patients with C. jejuni-related GBS.
101. Oomes PG, Jacobs BC, Hazenberg MPH, Banffer JR, van der Meche FG: Anti-GM1 antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann Neurol 1995, 38: 170-175.
102. Jacobs BC, Endtz H, van der Meche FGA, Hazenberg MP, Achtereekte HA, van Doom PA: Serum anti-GQ1b lgG antibodies recognise surface epltopes on Campylobacter jejuni form patients with Miller-Fisher syndrome. Ann Neurol 1995, 37:260-264.
103. Yuki N, Handa S, Tai T, Takahashi M, Saito K, Tsujino Y, Taki T: Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barré syndrome. J Neur Sci 1995, 130:112-116.
104. Cook SD, Rohowsky-Kochan C, Bansil S, Dowling PC: Evidence for multiple sclerosis as an infectious disease. Act Neurol Scand 1995, 161 (suppl) :34-42.
105. Liedtke W, Malessa R, Faustmann PM, Eis-Hübinger: Human herpervlrus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis. J Neurovirol 1995, 1:253-258.
106. Mitrovic B, Ignarro LJ, Montestruque S, Smoll A, Merrill JE: Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience 1994, 61:575-585.
107. Zielasek J, Reichmann H, Künzig H, Jung S, Hartung H-P, Toyka KV: Inhibition of brain macrophage/microglial replratory chain enzyme activity in experimental autoimmune encephalomyelitls of the Lewis rat Neurosci Lett 1995, 184:129-132
108. Bolanos JP, Heales SJR, Land JM, Clark JB: Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptlbility of neurones and astrocytes in primary culture. J Neurochem 1995, 64:1965-1972.
109. Johnson AW, Land JM, Thompson EJ, Bolanos P, Clark JB, Heales SJR: Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995, 58:107.
110. Bagasara O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, Tawadros R, Koprowski H: Activiation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A 1995, 92:12041-12045.
111. Brosnan CF, Cannella B, Battistini L, Raine CS: Cytoklne localisation in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive oxygen species. Neurology 1995, 45(suppl):S16-S21.
112. Bö L, Dawson TM, Wesselingh S, Mörk S, Choi S, Kong PA, Hanley D, Trapp BD: Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994, 36:778-786.
113. Ruuls S, Bauer J, Sontrop K, Huittinga I, t' Hart BA, Dijkstra CD: Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 1995, 56: 207-217.
114. Cross AH, Misko TP, Lin-RF, Hickey WF, Trotter JL, Tilton RG: Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994, 93:2684-2690.
115. Zielasek J, Jung S, Gold R, Liew FY, Toyka KV, Hartung HP: Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol 1995, 58:81-88.
116. Ozawa K, Suchanek G, Breitschopf H, Brück W, Budka H, Jellinger K, Lassmann H: Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994, 117:1311-1322.
117. Vartanian T, Li Y, Zhao M, Stefansson K: Interferon-γ-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med 1995, 7:732-743.
118. Wilt SG, Milward E, Zhou JM, Nagasalo K, Patton H, Rusten R, Griffin DE, O'Connor M, Dubois Dalcq M: In vitro evidence for a dual role of tumor necrosis factor-α in human immunodeficiency virus type I encepalo-pathy. Ann Neurol 1995, 37:381-394.
119. Brück W, Brück Y, Diederich U, Piddlesden SJ: The membrance attack complex of complement mediates peripheral nervous system demyelination in vitro. Acta Neuropathol 1995, 90:601-607.
120. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP: Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994, 152: 5477-5484.
121. Vriesendorp FJ, Flynn RE, Pappolla MA, Koski C: Complement depletion affects demyelination and inflammation in experimental neuritis. J Neuroimmunol 1995, 58:157-165.
122. Jung SJ, Toyka KV, Hartung H-P: Soluble complement receptor type I inhibits experimental autoimmune neuritis in Lewis rats. Neurosci Lett 1995, 200:167-200.
123. Koski CL, Estep AE, Sawant-Mane S, Shin ML, Highbarger L, Hansch M: Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. J Neurochem 1996, 66:303-312.
124. Pollard JD, Westland KW, Harvey GK, Jung S, Bonner J, Spies JM, Toyka KV, Hartung H-P: Activated T cells of nonneural specificity open the blood-nerve barrier to circulating antibody. Ann Neurol 1995, 37: 467-475.
125. Harvey GK, Gold R, Hartung H-P, Toyka KV: Non-neural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy. Brain 1995, 118:1263-1272.
126. Powell HC, Myers RR: The axon in Guillain-Barré syndrome: immune target or innocent bystander? Ann Neurol 1996, 39:4-5.
127. Lassmann H, Suchanek G, Ozawa K: Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994, 36:S42-56.
128. Davey CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, McDonald WI, Miller DH: Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axonal loss. Brain 1995, 118:1583-1592.
129. Kirschning E, Rutter G, Uhlig H, Dernick R: A sulfatide-reactive human monoclonal antibody obtained from a multiple sclerosis patient selectively binds to the surface of oligodendrocytes. J Neuroimmunol 1995, 56:191-200.
130. Flanagan EM, Erickson JB, Viveros OH, Chang SY, Reinhard JF Jr: Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis. J Neurochem 1995, 64: 1192-1196.
131. Rosengren LE, Lycke J, Andersen O: Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit J Neurol Sci 1995, 133:61-65.
132. Neumann H, Cavalie A, Jenne DE, Wekerle H: induction of MHC class I •• gene in neurons. Science 1995, 269:549-552. Important observation that neurons are able to express MHC class I antigens and are therefore liable to attack by cytotoxic T lymphocytes. Transcription of MHC I genes occurred only in electrically silent neurons. This has important implications for the immunology of neurotropic viruses and neuronal transplantation.
133. ••].
134. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM: Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995, 118:597-605.